Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors

European Journal of Cancer

Volumn 82, Issue , 2017, Pages 128-136

  Makarious, D ^a   Horwood, K ^b   Coward, J I G ^b,c,d  

^a BOND UNIVERSITY   (Australia)

^b ICON Cancer Care   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Autoimmunity; CTLA 4; Immune checkpoint inhibitors; Immune related adverse events; Ipilimumab; Myasthenia gravis; Nivolumab; PD 1; Pembrolizumab

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNE CHECKPOINT INHIBITOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; PEMBROLIZUMAB; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; PYRIDOSTIGMINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1;

AGED; AXILLARY LYMPH NODE; CARDIOVASCULAR MORTALITY; CASE REPORT; DIPLOPIA; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOTOXICITY; LYMPHADENOPATHY; MAINTENANCE THERAPY; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; PRIORITY JOURNAL; PTOSIS; REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE; VERY ELDERLY; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; IMMUNOTHERAPY;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; FEMALE; HUMANS; IMMUNOTHERAPY; MYASTHENIA GRAVIS;

EID: 85021263317     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.05.041     Document Type: Review

References (34)

1. March, K.L., Samarin, M.J., Sodhi, A., Owens, R.E., Pembrolizumab-induced myasthenia gravis: a fatal case report. J Oncol Pharm Pract, 2017 Jan 1 1078155216687389.
2. Gonzalez, N.L., Puwanant, A., Lu, A., Marks, S.M., Živković, S.A., Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord 27 (2017), 266–268.
3. Nguyen, B.H.V., Kuo, J., Budiman, A., Christie, H., Ali, S., Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res 27 (2017), 152–154.
4. Shirai, T., Sano, T., Kamijo, F., Saito, N., Miyake, T., Kodaira, M., et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 46 (2016), 86–88.
5. Kimura, T., Fukushima, S., Miyashita, A., Aoi, J., Jinnin, M., Kosaka, T., et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107 (2016), 1055–1058.
6. Zimmer, L., Goldinger, S.M., Hofmann, L., Loquai, C., Ugurel, S., Thomas, I., et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60 (2016), 210–225.
7. Alnahhas, I., Wong, J., A case of new onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma. Muscle Nerve 55:6 (2017 Jun), E25–E26.
8. Polat, P., Donofrio, P.D., Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle Nerve, 54, 2016, 507.
9. Sciacca, G., Nicoletti, A., Rampello, L., Noto, L., Parra, H.J.S., Zappia, M., Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve 54 (2016), 507–509.
10. Chang, E., Sabichi, A.L., Sada, Y.H., Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder. J Immunother 40 (2017), 114–116.
11. Lopez, D., Calvao, A., Fershko, A., Myasthenia gravis and rhabdomyolysis in a patient with advanced renal cell cancer treated with nivolumab: a case report and review of the literature. Br J Med Health Res 2 (2015), 11–16.
12. Liao, B., Shroff, S., Kamiya-Matsuoka, C., Tummala, S., Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16 (2014), 589–593.
13. Johnson, D.B., Saranga-Perry, V., Lavin, P.J.M., Burnette, W.B., Clark, S.W., Uskavitch, D.R., et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 33 (2015), e122–e124.
14. Montes, V., Sousa, S., Guerreiro, R., Carmona, C., Pita, F., Myasthenia gravis induced by ipilimumab in a patient with advanced melanoma. Eur J Nuerol, 23, 2016, 548.
15. Antonia, S., Goldberg, S.B., Balmanoukian, A., Chaft, J.E., Sanborn, R.E., Gupta, A., et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17 (2016), 299–308.
16. Loochtan, A.I., Nickolich, M.S., Hobson-Webb, L.D., Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 52 (2015), 307–308.
17. Antonia, S.J., López-Martin, J.A., Bendell, J., Ott, P.A., Taylor, M., Eder, J.P., et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17 (2016), 883–895.
18. Lau, K.H.V., Kumar, A., Yang, I.H., Nowak, R.J., Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve 54 (2016), 157–161.
19. Maeda, O., Yokota, K., Atsuta, N., Katsuno, M., Akiyama, M., Ando, Y., Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci 78 (2016), 119–122.
20. Phadke, S.D., Ghabour, R., Swick, B.L., Swenson, A., Milhem, M., Zakharia, Y., Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease. J Investig Med High Impact Case Rep, 4, 2016 232470961667431.
21. Zhu, J., Li, Y., Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve 54 (2016), 506–507.
22. Spain, L., Diem, S., Larkin, J., Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44 (2016), 51–60.
23. Brahmer, J.R., Tykodi, S.S., Chow, L.Q.M., Hwu, W.-J., Topalian, S.L., Hwu, P., et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
24. Meriggioli, M.N., Sanders, D.B., Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8 (2009), 475–490.
25. Ueda, H., Howson, J.M., Esposito, L., Heward, J., Snook, H., Chamberlain, G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423 (2003), 506–511.
26. Topalian, S.L., Sharpe, A.H., Balance and imbalance in the immune system: life on the edge. Immunity 41 (2014), 682–684.
27. Waterhouse, P., Penninger, J.M., Timms, E., Wakeham, A., Shahinian, A., Lee, K.P., et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270 (1995), 985–988.
28. Chuang, W.Y., Strobel, P., Gold, R., Nix, W., Schalke, B., Kiefer, R., et al. A CTLA4 high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol 58 (2005), 644–648.
29. Wang, X.B., Pirskanen, R., Giscombe, R., Lefvert, A.K., Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. J Intern Med 263 (2008), 61–69.
30. Sun, L., Meng, Y., Xie, Y., Zhang, H., Zhang, Z., Wang, X., et al. CTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in northern Chinese population. PLoS One, 9, 2014, e101986.
31. Calabrese, L., Velcheti, V., Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases. Ann Rheum Dis 76 (2017), 1–3.
32. McKinney, E.F., Lee, J.C., Jayne, D.R., Lyons, P.A., Smith, K.G., T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523 (2015), 612–616.
33. Lindstrom, J.M., Seybold, M.E., Lennon, V.A., Whittingham, S., Duane, D.D., Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. 1975. Neurology, 51, 1998 933 and 6 pages following.
34. Menzies, A.M., Johnson, D.B., Ramanujam, S., Atkinson, V.G., Wong, A.N.M., Park, J.J., et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol, 2016, mdw443.